Neoplasm Recurrence Clinical Trials

2 recruiting

Neoplasm Recurrence Trials at a Glance

7 actively recruiting trials for neoplasm recurrence are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Aarhus, Bergen, and Bodø. Lead sponsors running neoplasm recurrence studies include Shandong Cancer Hospital and Institute, Centre Hospitalier Universitaire de la Guadeloupe, and Danish Breast Cancer Cooperative Group.

Browse neoplasm recurrence trials by phase

Treatments under study

About Neoplasm Recurrence Clinical Trials

Looking for clinical trials for Neoplasm Recurrence? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasm Recurrence trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasm Recurrence clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Phase 3

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Bladder CancerUrothelial Carcinoma BladderNeoplasm Recurrence+3 more
Verity Pharmaceuticals Inc.540 enrolled6 locationsNCT05037279
Recruiting
Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Not Applicable

Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.

Neoplasm MetastasisAdenocarcinomaProstatic Neoplasm+1 more
Centre Hospitalier Universitaire de la Guadeloupe3,000 enrolled2 locationsNCT06046131
Recruiting
Phase 2

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Cervical CancerOligometastaticNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute36 enrolled1 locationNCT06942416
Recruiting
Phase 3

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Recruiting
Not Applicable

Partial Breast Versus no Irradiation for Women With Early Breast Cancer

Local Neoplasm RecurrenceDistantly Metastatic Malignant NeoplasmDeath+6 more
Danish Breast Cancer Cooperative Group926 enrolled17 locationsNCT03646955